Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway.
Cicala CM, Matito J, Quindos M, Gómez-Peregrina D, Romero-Lozano P, Fernández-Suárez P, Valverde C, González M, Landolfi S, Pérez-Albert P, Gros L, Vivancos A, Serrano C. Cicala CM, et al. Among authors: valverde c. JCO Precis Oncol. 2025 Jan;9:e2400497. doi: 10.1200/PO-24-00497. Epub 2025 Jan 9. JCO Precis Oncol. 2025. PMID: 39787462
Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models.
Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados AP, Uriarte-Arrazola I, Mazuelas H, Blanco I, Valverde C, Carrió M, Villanueva A, De Raedt T, Romagosa C, Gel B, Salvador H, Ferrer M, Lázaro C, Serra E. Ortega-Bertran S, et al. Among authors: valverde c. Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-2807. Online ahead of print. Clin Cancer Res. 2024. PMID: 39786423
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.
Salazar J, Arranz MJ, Martin-Broto J, Bautista F, Martínez-García J, Martínez-Trufero J, Vidal-Insua Y, Echebarria-Barona A, Díaz-Beveridge R, Valverde C, Luna P, Vaz-Salgado MA, Blay P, Álvarez R, Sebio A. Salazar J, et al. Among authors: valverde c. Pharmaceutics. 2024 Dec 12;16(12):1585. doi: 10.3390/pharmaceutics16121585. Pharmaceutics. 2024. PMID: 39771563 Free PMC article.
A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
Livingston JA, Blay JY, Trent J, Valverde C, Agulnik M, Gounder M, Le Cesne A, McKean M, Wagner MJ, Stacchiotti S, Agresta S, Quintás-Cardama A, Reilly SA, Healy K, Hickman D, Zhao T, Ballesteros-Perez A, Khalil A, Collins MP, Piel J, Horrigan K, Lefkovith A, Innis S, Lazar AJ, Cote GM, Wagner AJ. Livingston JA, et al. Among authors: valverde c. Clin Cancer Res. 2024 Dec 11. doi: 10.1158/1078-0432.CCR-24-2583. Online ahead of print. Clin Cancer Res. 2024. PMID: 39660994
Investigation of the linear and nonlinear optical properties in the crystalline phase of a pyrimidine derivative-a potential nonlinear optical material: analysis of its structure, reactivity, and docking studies.
Potla KM, Asiri YI, Rani NU, Osório FAP, Valverde C, Raja M, Armaković SJ, Armaković S. Potla KM, et al. Among authors: valverde c. RSC Adv. 2024 Nov 26;14(51):37709-37724. doi: 10.1039/d4ra05681g. eCollection 2024 Nov 25. RSC Adv. 2024. PMID: 39601005 Free PMC article.
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.
Palmerini E, Lopez Pousa A, Grignani G, Redondo A, Hindi N, Provenzano S, Sebio A, Lopez Martin JA, Valverde C, Martinez Trufero J, Gutierrez A, de Alava E, Aparisi Gomez MP, D'Ambrosio L, Collini P, Bazzocchi A, Moura DS, Ibrahim T, Stacchiotti S, Broto JM. Palmerini E, et al. Among authors: valverde c. Cancer. 2025 Jan 1;131(1):e35628. doi: 10.1002/cncr.35628. Epub 2024 Nov 14. Cancer. 2025. PMID: 39540661 Free PMC article. Clinical Trial.
Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.
Mondaza-Hernandez JL, Hindi N, Fernandez-Serra A, Ramos R, Gonzalez-Cámpora R, Gómez-Mateo MC, Martinez-Trufero J, Lavernia J, Lopez-Pousa A, Laínez N, Martinez-Garcia J, Valverde C, Vaz-Salgado MÁ, Garcia-Plaza G, Marin-Borrero I, Carrillo-Garcia J, Martin-Ruiz M, Romero P, Gutierrez A, López-Guerrero JA, Moura DS, Martin-Broto J. Mondaza-Hernandez JL, et al. Among authors: valverde c. Ther Adv Med Oncol. 2024 Nov 4;16:17588359241293951. doi: 10.1177/17588359241293951. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502403 Free PMC article.
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Martin-Broto J, Diaz-Beveridge R, Moura D, Ramos R, Martinez-Trufero J, Carrasco I, Sebio A, González-Billalabeitia E, Gutierrez A, Fernandez-Jara J, Hernández-Vargas L, Cruz J, Valverde C, Hindi N. Martin-Broto J, et al. Among authors: valverde c. J Clin Oncol. 2024 Oct 2:JCO2400358. doi: 10.1200/JCO.24.00358. Online ahead of print. J Clin Oncol. 2024. PMID: 39356980
299 results